Push release material from World Newswire. The AP news staff members was not included in its creation.
Company announcement – No. 1 / 2021
- Web working bills in 2020 are envisioned to be above the earlier guided selection of DKK 950-1,000 million by close to 5-10%.
Copenhagen, January 22, 2021 – with reference to the corporation announcement dated 12 November 2020 (interim report for the time period 1 January 2020 to 30 September 2020), Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company concentrated on the discovery, growth and commercialization of impressive peptide-centered medications, announces an update to the economic direction for 2020 (based on preliminary and unaudited figures).
Zealand expects increased basic functioning expenditure advice by approximately 5-10% (overall operating fees of DKK 1,050 million to 1,100 million).
Zealand will announce the in depth and audited monetary success, and expects to provide outlook for 2021, in the 2020 Annual Report to be released on 11 March 2021.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology organization concentrated on the discovery, improvement and commercialization of progressive peptide-based medicines. A lot more than 10 drug candidates invented by Zealand have highly developed into clinical development, of which two have attained the market place. Zealand’s sturdy pipeline of investigational medicines features three candidates in late stage improvement, and just one candidate currently being reviewed for regulatory acceptance in the United States. Zealand markets V-Go®, an all-in-one particular basal-bolus insulin supply option for individuals with diabetes. License collaborations with Boehringer Ingelheim and Alexion Prescription drugs build possibility for far more patients to most likely benefit from Zealand-invented peptide therapeutics.
Zealand was launched in 1998 in Copenhagen, Denmark, and has presence in the course of the U.S. that includes important locations in New York, Boston, and Marlborough (MA). For extra data about Zealand’s company and actions, remember to check out www.zealandpharma.com.
For even further info, make sure you call:
Head of Trader Relations & Interaction
Phone: +45 5060 3707
E-mail: [email protected]
For U.S. Media
Cellular phone: 212-600-1902
Electronic mail: [email protected]